425: Waters to Acquire BD's Biosciences & Diagnostic Solutions Unit

Waters Corporation is set to acquire Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business in a Reverse Morris Trust transaction valued at approximately $17.5 billion, aiming for significant growth and synergies.

Summary

• Waters Corporation will acquire Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions (BDS) business through a Reverse Morris Trust transaction.
• The transaction involves BD contributing the BDS Business to Augusta SpinCo Corporation (SpinCo), distributing SpinCo common stock to BD shareholders, and then SpinCo merging with a Waters subsidiary.
• The BDS Business is valued at approximately $17.5 billion, based on Waters' stock price of $349.02 as of July 11, 2025.
• Post-merger, former SpinCo holders (BD shareholders) are expected to own approximately 39.2% of Waters' fully diluted common stock, while pre-merger Waters shareholders will own approximately 60.8%, subject to tax-driven adjustments.
• SpinCo will make a $4.0 billion cash distribution to BD, funded by new indebtedness, which BD plans to use at least half for share repurchases.
• The combined company is projected to achieve $345 million in annualized run-rate Adjusted EBITDA synergies by year five, comprising $200 million in cost synergies by year three and $290 million in revenue synergies by year five.
• The transaction is expected to be accretive to Waters' adjusted earnings per share in the first year following the closing.
• The Waters Board of Directors unanimously approved the merger and recommends shareholders vote for the Share Issuance Proposal.
• The merger is expected to close around the end of the first quarter of calendar year 2026, subject to regulatory and shareholder approvals.

Sentiment

Score: 8

Explanation: The filing presents a highly strategic and financially beneficial merger with strong projected synergies and growth, unanimously approved by the Waters Board. While risks and potential delays are acknowledged, the overall tone and outlook are very positive, indicating high confidence in the transaction's success.

Positives

• The transaction is expected to accelerate Waters' business strategy and provide significant value creation opportunities and financial benefits for Waters and its shareholders.
• The combined company is projected to double Waters' accessible market to approximately $40.0 billion, expanding into high-growth adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics.
• An accelerated innovation pipeline and commercial capabilities are expected, with a projected R&D spend of 10% of annual product sales, driving revenue generation and strengthening earnings growth.
• Waters' management believes it can successfully apply its transformation drivers (e.g., increasing service attachment from 43% to over 50%, growing eCommerce adoption by over 20%) to the BDS Business.
• The combined company is expected to be a leader in life science and diagnostics, with estimated sales of approximately $6.5 billion and Adjusted EBITDA of approximately $2.0 billion in calendar year 2025.
• The combination of Waters' chemistry expertise and BDS Business's biologics expertise is expected to expand the portfolio with next-generation consumables and drive growth in biologics and novel modalities.
• Approximately 70% of the combined company's revenue is expected to be recurring annually, with over 80% from market-leading brands, leading to more predictable, high single-digit growth and significant margin expansion.
• The combined company is expected to have a strong cash-generation profile, converting approximately $0.20 of every dollar of revenue into free cash flow beginning in 2026, increasing to $0.25 by 2029.
• The combination is expected to enhance Waters' overall credit quality over time through increased scale and breadth, and the ability to sustain a debt to EBITDA ratio below 2.0x.
• The Reverse Morris Trust structure provides a tax-efficient method for the separation and combination, limiting the combined company's total leverage compared to an all-cash transaction.

Negatives

• The BDS Business experienced supply issues with BACTEC bottle products in fiscal year 2024 due to reduced availability of blood culture vials, negatively impacting financial performance and microbiology platform sales.
• Customer utilization for BACTEC blood culture products has not recovered to pre-disruption levels even after production recovered in fiscal year 2025.
• The BDS Business was negatively impacted by a reduction in government funding to customers in fiscal year 2025.
• Waters implemented a workforce reduction of approximately 2% of its employees, primarily in China, in March 2024 due to lower customer demand.
• The BDS Business recorded a $17 million accrual in fiscal year 2024 related to the Italian government medical device pay-back legislation, which negatively impacted gross margin.

Risks

• The consummation of the Transactions is subject to significant risks and uncertainties and may not be completed on expected terms or at all, potentially leading to increased transaction costs and professional fees.
• The pending Transactions may disrupt Waters' business operations and relationships with customers, suppliers, and employees, potentially affecting retention and recruitment of key personnel.
• The amount of the Waters Special Dividend, if any, and the number of Waters Common Stock shares issued is uncertain and depends on shareholder overlap and IRS rulings, potentially diluting existing Waters shareholders.
• The merger consideration is fixed and will not be adjusted for changes in the value of the BDS Business or Waters before completion, potentially leading to a market price decline if perceived benefits are not realized.
• The Merger Agreement contains provisions, such as a $733.0 million termination fee payable by Waters, that may discourage alternative acquisition proposals for Waters.
• If the Contribution and Distribution do not qualify as tax-free under Sections 355 and 368(a) of the Code, BD and its shareholders may face substantial U.S. federal income taxes, and SpinCo (as a Waters subsidiary) may be obligated to indemnify BD for such taxes.
• If the Merger does not qualify as a reorganization under Section 368(a) of the Code, BD shareholders may be required to pay substantial U.S. federal income taxes.
• Negative publicity related to the Transactions could adversely affect Waters, BD, and the combined company's reputation, employee morale, and relationships with stakeholders.
• Lawsuits challenging the Transactions could delay or prevent closing and result in significant costs and adverse impacts on the combined company's business.
• Waters' failure to successfully integrate the BDS Business within the expected timeline could adversely affect future results, including failure to realize anticipated synergies.
• The combined company will incur substantial indebtedness, which could adversely affect operational flexibility, increase borrowing costs, and limit investment capacity.
• Restrictions imposed by tax laws and the Tax Matters Agreement could limit the combined company's ability to undertake certain corporate actions that might otherwise be advantageous.
• The historical financial statements of the BDS Business may not be representative of its performance as an independent entity, and actual results may differ materially from pro forma financial information.
• The combined company may be unable to replace services historically provided by BD or obtain them at comparable costs, adversely affecting operations.
• International operations are exposed to political events, wars, terrorism, economic conditions, and regulatory changes, including trade protectionism and foreign currency fluctuations.
• Global economic conditions, such as inflation and interest rates, may adversely affect demand for and supply of the combined company's products.
• Public health crises, epidemics, or pandemics could negatively impact the combined company's business, sales, and cash flow.
• Competition from more effective or less expensive products, or industry consolidation, could result in decreased sales.
• Failure to develop new technologies and bring them to market in a timely manner could negatively impact financial results.
• Reductions in customer research budgets or government funding may adversely affect the business.
• Defects or quality issues with products could lead to recalls, product liability claims, and reputational damage.
• Issues and uncertainties related to the development, deployment, and use of artificial intelligence in business operations and products may result in harm to reputation, regulatory action, or legal liability.
• Disruption of operations, including at manufacturing facilities or key technology systems (like ERP implementation), could materially impact the business.
• Failure to adequately protect intellectual property could have materially adverse effects on results of operations or financial condition.
• Inability to acquire adequate sources of supply, especially for sole-sourced components, could disrupt manufacturing and sales.
• Actions of third-party sales intermediaries and other third parties selling products could harm the business.
• Changes in governmental regulations and compliance failures, including those related to healthcare, data privacy, and environmental laws, could harm the business.
• The combined company may be subject to litigation and other legal and regulatory proceedings in the ordinary course of business.
• The effects of climate change, including stricter environmental standards and severe weather events, could harm the business.
• Inaccurate accounting estimates and assumptions, particularly for revenue recognition, goodwill, intangible assets, and income taxes, could materially differ from actual results.

Future Outlook

The combined company anticipates 7% top-line and mid-teens adjusted EPS annualized CAGR growth between 2025 and 2030. It expects to convert approximately $0.20 of every revenue dollar into free cash flow starting in 2026, increasing to $0.25 by 2029. The gross debt level at closing is projected to be around 2.6x, assuming no Exchange Ratio adjustment. Waters does not anticipate the special dividend to be triggered based on current shareholder overlap analysis. The combined entity expects to incur additional costs for restructuring and streamlining operations and plans to launch new microbiology products, with significant sales expected in three to five years.

Management Comments

• Dr. Udit Batra, Waters President and CEO, stated, 'This transaction is a natural extension of our strategy and transformation to become a pioneering life science tools and diagnostics leader with an industry-leading financial outlook.'
• Dr. Batra also commented, 'We believe our execution model will bring the focus, rigor, and operational excellence needed for these businesses to thrive.'
• Dr. Batra emphasized, 'The combined business is poised for significant value creation.'
• Dr. Batra noted, 'Our teams are working hard to plan for integration, led by a team who has extensive experience in large-scale integrations. We are as confident as ever that bringing BDs Biosciences & Diagnostic Solutions business into Waters positions us exceptionally well to build on our momentum and deliver value to shareholders.'
• The Waters Board of Directors 'strongly recommends that shareholders should support the transaction and vote FOR each of the proposals to be considered at the Special Meeting.'
• The BD Board believed 'the Transactions would provide more value to BD and BD shareholders than other potential strategic options for the BDS Business or retaining the BDS Business.'
• The BD Board also stated that 'the Transactions are expected to sharpen BDs focus and leadership as a scaled, pure-play medical technology company.'
• The BD Board highlighted that 'the Transactions are expected to enhance BDs capital allocation as a result of BDs receipt of $4.0 billion of cash and the use of at least half of that cash for share repurchases.'

Industry Context

The transaction positions Waters to expand significantly into high-growth adjacent end markets, leveraging its chemistry expertise with BD's biologics prowess in bioseparations, bioanalytical characterization, and multiplex diagnostics. The combined entity aims to deploy BD's flow cytometry into quality assurance systems and bring mass spectrometry to specialty diagnostics. Both companies are recognized for pioneering science and innovation. The analytical instrument market is highly competitive and characterized by rapid technological change and frequent product introductions. The industry is also experiencing a global trend towards limiting healthcare costs and increasing global protectionism, which could impact market access and competition.

Comparison to Industry Standards

• Waters' management noted that BD's Biosciences & Diagnostic Solutions business, in many ways, resembles Waters from five years ago, suggesting a similar growth trajectory and transformation potential.
• Waters has a proven track record of accelerating growth through acquisitions (e.g., Wyatt Technologies, Halo Labs) and partnerships (e.g., University of Delaware, Princeton University, Washington University), which it plans to apply to the BDS Business.
• Both Waters' liquid chromatography and BD's flow cytometry instrumentation have supported Nobel Prize-winning research, indicating a high standard of scientific contribution.
• Waters' management identified 'certain elements of underperformance of the BDS Business relative to its key competitors,' suggesting an opportunity for improvement under Waters' management.
• The combined company's projected 7% top-line and mid-teens adjusted EPS annualized CAGR growth from 2025-2030 is described as an 'industry-leading financial outlook,' implying a strong performance relative to peers.
• The combined company's expected annual recurring revenue of over 70% and over 80% of revenue from 'iconic market-leading brands' positions it favorably for predictable growth compared to industry averages.

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuits may be filed against Waters, SpinCo, BD, the combined company, and/or their directors challenging the Transactions, which could prevent or delay closing and incur significant costs.
• The BDS Business, along with other medical device companies, has filed appeals challenging the enforceability of Italian government medical device pay-back legislation.
• In July 2024, the Italian Constitutional Court ruled the medical device payback legislation constitutional.
• The BDS Business accrued $17 million in fiscal year 2024 for the Italian legislation liability, primarily relating to years prior to 2024.
• In Q4 fiscal year 2025, the BDS Business settled its Italian obligations for 2015-2018 by paying 25% of invoiced amounts, but ultimate resolution for later years is unknown.
• BD is currently undergoing tax audits by the IRS for fiscal years 2018 through 2023, with other major tax jurisdictions generally open after 2016.

Related Party Transactions

• The transaction itself is a related party transaction between BD (parent) and its subsidiary SpinCo, which will merge with Waters.
• Intercompany agreements between members of the SpinCo Group and the Company Group (BD and its other subsidiaries) will be terminated at the Distribution Time, with certain exceptions.
• All intercompany receivables and payables between the SpinCo Group and the Company Group outstanding immediately prior to the Distribution Time will be repaid, settled, or eliminated.
• A Transition Services Agreement will be entered into, under which BD will provide various services (HR, sales, marketing, finance, IT) to SpinCo on a transitional basis for 3 to 24 months.
• One or more Contract Manufacturing Agreements will be established, where BD and SpinCo will manufacture certain components for each other with minimum purchase requirements.
• An Intellectual Property Matters Agreement will be entered into, granting BD and Waters non-exclusive, royalty-free, irrevocable licenses to certain intellectual property, and BD granting Waters an exclusive license to three R&D-stage patent families.
• An Employee Matters Agreement will govern the transfer of employment for SpinCo employees and the allocation of related assets and liabilities, including the conversion of BD equity awards to Waters awards.
• Waters' Related Party Transactions Policy covers 'Interested Transactions' exceeding $120,000 involving related parties, with certain categories (e.g., NEO compensation, director compensation, charitable contributions, ordinary course business with specific companies where directors hold positions) deemed pre-approved or ratified.

Stakeholder Impact

• **Waters Shareholders**: Will experience dilution of ownership and voting interest (from 100% to 60.8%-49.5%) in the combined company. May receive a special dividend if tax-related exchange ratio adjustments are triggered. Expected to benefit from significant value creation, accelerated growth, and enhanced financial outlook.
• **BD Shareholders**: Will receive shares of Waters Common Stock in exchange for their SpinCo Common Stock and will retain their BD Common Stock, which will represent an interest in BD excluding the BDS Business. Expected to benefit from value creation and enhanced capital allocation for BD.
• **SpinCo/BDS Business Employees**: May experience uncertainty regarding future roles. Equity awards will convert to Waters awards, with accelerated vesting provisions for certain terminations post-merger. Compensation and benefits are expected to be no less favorable for 12 months post-closing.
• **Customers**: Potential for disruption to existing business relationships due to the transaction. Expected benefits include an expanded portfolio, accelerated innovation, and improved service capabilities from the combined entity.
• **Suppliers**: May face uncertainty regarding existing relationships and potential renegotiation of terms.
• **Creditors**: The combined company will incur substantial new indebtedness, which could impact its credit ratings, borrowing costs, and financial flexibility.
• **Management**: Waters' existing CEO and CFO will lead the combined company, with increased responsibilities. The Waters Board will include 1-2 BD nominees. BD's management will focus on the remaining medical technology business.

Next Steps

• Waters shareholders will vote on the Share Issuance Proposal at a Special Meeting on January 27, 2026.
• The Merger is expected to close around the end of the first quarter of calendar year 2026.
• BD will publicly announce the record date for the Distribution.
• BD will continue to pursue the IRS Ruling regarding the tax treatment of the transaction.
• Waters will file an application with the NYSE for the listing of the shares of Waters Common Stock to be issued in the Merger.
• Integration planning for the combined company's operations will continue.
• The combined company expects to incur additional costs and restructuring charges related to manufacturing, supply chain, and business function streamlining.
• New microbiology products are expected to be brought to market, with significant sales anticipated in three to five years.

Key Dates

Recommendation

The transaction is a highly strategic move for Waters, expanding its market reach into high-growth life sciences and diagnostics segments. The projected $345 million in annualized Adjusted EBITDA synergies and anticipated 7% top-line and mid-teens adjusted EPS CAGR growth from 2025-2030 demonstrate a compelling financial rationale. The unanimous board approval and the tax-efficient Reverse Morris Trust structure further underscore confidence in the value creation potential. While integration risks and increased debt are present, the expected long-term benefits and strong cash generation profile make this a highly attractive investment opportunity.

Keywords

Life Sciences, Diagnostics, Analytical Instruments, Merger, Acquisition, Reverse Morris Trust, Spin-off, Flow Cytometry, Mass Spectrometry, Microbiology, Bioseparations, Biotechnology, Healthcare, Medical Devices, SEC Filing, Waters Corporation, Becton Dickinson, Augusta SpinCo